|
1
|
Demers B, Simor AE, Vellend H, Schlievert
PM, Byrne S, Jamieson F, Walmsley S and Low DE: Severe invasive
group A streptococcal infections in Ontario, Canada: 1987-1991.
Clin Infect Dis. 16:792–800; discussion 801-2. 1993.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rodríguez-Nuñez A, Dosil-Gallardo S and
Jordan I: ad hoc Streptococcal Toxic Shock Syndrome collaborative
group of Spanish Society of Pediatric Intensive Care. Clinical
characteristics of children with group A streptococcal toxic shock
syndrome admitted to pediatric intensive care units. Eur J Pediatr.
170:639–644. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yamakawa K, Umemura Y, Hayakawa M, Kudo D,
Sanui M, Takahashi H, Yoshikawa Y, Hamasaki T and Fujimi S: Japan
Septic Disseminated Intravascular Coagulation (J-Septic DIC) study
group. Benefit profile of anticoagulant therapy in sepsis: A
nationwide multicentre registry in Japan. Crit Care.
20(229)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Stevens DL, Tanner MH, Winship J, Swarts
R, Ries KM, Schlievert PM and Kaplan E: Severe group A
streptococcal infections associated with a toxic shock-like
syndrome and scarlet fever toxin A. N Engl J Med. 321:1–7.
1989.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Defining the group A streptococcal toxic
shock syndrome. Rationale and consensus definition. The Working
Group on Severe Streptococcal Infections. JAMA. 269:390–391.
1993.PubMed/NCBI
|
|
6
|
Wada H, Takahashi H, Uchiyama T, Eguchi Y,
Okamoto K, Kawasugi K, Madoiwa S and Asakura H: DIC subcommittee of
the Japanese Society on Thrombosis and Hemostasis. The approval of
revised diagnostic criteria for DIC from the Japanese Society on
Thrombosis and Hemostasis. Thromb J. 15(17)2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wong CH, Khin LW, Heng KS, Tan KC and Low
CO: The LRINEC (Laboratory Risk Indicator for Necrotizing
fasciitis) score: A tool for distinguishing necrotizing fasciitis
from other soft tissue infections. Crit Care Med. 32:1535–1541.
2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Okuzono S, Ishimura M, Kanno S, Sonoda M,
Kaku N, Motomura Y, Nishio H, Oba U, Hanada M, Fukushi JI, et al:
Streptococcus pyogenes-purpura fulminans as an invasive form
of group A streptococcal infection. Ann Clin Microbiol Antimicrob.
17(31)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Meuleman DG: Orgaran (Org 10172): Its
pharmacological profile in experimental models. Haemostasis.
22:58–65. 1992.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tsuruta K, Yamada Y, Serada M and
Tanigawara Y: Model-based analysis of covariate effects on
population pharmacokinetics of thrombomodulin alfa in patients with
disseminated intravascular coagulation and normal subjects. J Clin
Pharmacol. 51:1276–1285. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hayakawa M, Kushimoto S, Watanabe E, Goto
K, Suzuki Y, Kotani T, Kiguchi T, Yatabe T, Tagawa J, Komatsu F and
Gando S: Pharmacokinetics of recombinant human soluble
thrombomodulin in disseminated intravascular coagulation patients
with acute renal dysfunction. Thromb Haemost. 117:851–859.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Saito H, Maruyama I, Shimazaki S, Yamamoto
Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M
and Aoki N: Efficacy and safety of recombinant human soluble
thrombomodulin (ART-123) in disseminated intravascular coagulation:
Results of a phase III, randomized, double-blind clinical trial. J
Thromb Haemost. 5:31–41. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shirahata A, Mimuro J, Takahashi H, Tsuji
H, Kitajima I, Matsushita T, Eguchi Y, Kitamura N, Honda G and
Sakata Y: Postmarketing surveillance of recombinant human soluble
thrombomodulin (thrombomodulin α) in pediatric patients with
disseminated intravascular coagulation. Clin Appl Thromb Hemost.
20:465–472. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bradbrook ID, Magnani HN, Moelker HC,
Morrison PJ, Robinson J, Rogers HJ, Spector RG, Van Dinther T and
Wijnand H: ORG 10172: A low molecular weight heparinoid
anticoagulant with a long half-life in man. Br J Clin Pharmacol.
23:667–675. 1987.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hobbelen PM, Vogel GM and Meuleman DG:
Time courses of the antithrombotic effects, bleeding enhancing
effects and interactions with factors Xa and thrombin after
administration of low molecular weight heparinoid Org 10172 or
heparin to rats. Thromb Res. 48:549–558. 1987.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yamakawa K, Ogura H, Fujimi S, Morikawa M,
Ogawa Y, Mohri T, Nakamori Y, Inoue Y, Kuwagata Y, Tanaka H, et al:
Recombinant human soluble thrombomodulin in sepsis-induced
disseminated intravascular coagulation: A multicenter propensity
score analysis. Intensive Care Med. 39:644–652. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gando S, Levi M and Toh CH: Disseminated
intravascular coagulation. Nat Rev Dis Primers.
2(16037)2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Weitz JI and Bates SM: New anticoagulants.
J Thromb Haemost. 3:1843–1853. 2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hirsh J, Warkentin TE, Shaughnessy SG,
Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM and Dalen JE:
Heparin and low-molecular-weight heparin: Mechanisms of action,
pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest.
119 (Suppl):64S–94S. 2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wilde MI and Markham A: Danaparoid. A
review of its pharmacology and clinical use in the management of
heparin-induced thrombocytopenia. Drugs. 54:903–924.
1997.PubMed/NCBI View Article : Google Scholar
|
